
8-K
1
ea121272-8k_chardanhealth.htm
CURRENT REPORT



     







 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

 

Form
8-K

 

Current
Report

Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

April
28, 2020

Date
of Report (Date of earliest event reported)

 

Chardan
Healthcare Acquisition 2 Corp.

(Exact
Name of Registrant as Specified in its Charter)

 



    Delaware
     
    001-39271
     
    83-3169838

    (State or other jurisdiction
    of incorporation) 
     
    (Commission File
    Number)
     
    (I.R.S. Employer
    Identification No.)

 



    17
        State Street, 21st Floor
        New
        York, NY
     
    10004

    (Address of Principal
    Executive Offices)
     
    (Zip Code)

 

Registrant’s
telephone number, including area code: (646) 465-9000

  

N/A

(Former
name or former address, if changed since last report)

 

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

 


☐Written
communications pursuant to Rule 425 under the Securities Act

 


☐Soliciting
material pursuant to Rule 14a-12 under the Exchange Act

 


☐Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act

 


☐Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities
registered pursuant to Section 12(b) of the Act:

 



    Title
    of each class
     
    Trading
    Symbol(s)
     
    Name
    of each exchange on 
    which registered

    Common Stock
     
    CHAQ
     
    NYSE American, LLC

    Warrants
     
    CHAQW
     
    NYSE American, LLC

    Units
     
    CHAQU
     
    NYSE American, LLC

 

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging
growth company ☒

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  



 

 



     
     
    

 

Item 8.01. Other Events

 

As previously disclosed on a Current
Report on Form 8-K dated April 23, 2020, on April 28, 2020 Chardan Healthcare Acquisition 2 Corp. (the “Company”)
consummated the IPO of 8,500,000 units (the “Units”). Each Unit consists of one share of common stock
(“Common Stock”) and one warrant (“Warrant”) entitling its holder to purchase one-half share of
Common Stock at a price of $11.50 per whole share. The Units were sold at an offering price of $10.00 per Unit, generating
gross proceeds of $85,000,000.

 

As of April 28, 2020, a total of $85,000,000
of the net proceeds from the IPO and the private placement consummated simultaneously with the closing of the IPO were deposited
in a trust account established for the benefit of the Company’s public stockholders.

 

An audited balance sheet as of April 28,
2020 reflecting receipt of the proceeds upon consummation of the IPO and the private placement is included with this report as
Exhibit 99.1

 

Item 9.01. Financial Statements and Exhibits.

 



    Exhibit
    No.
     
    Description

     
     
     

    99.1
     
    Balance Sheet dated April 28, 2020

 





    1
     
    


 

SIGNATURES

 

Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 4, 2020

 

CHARDAN HEALTHCARE ACQUISITION 2 CORP.

 



    By: 
    /s/ Jonas Grossman
     

    Name: 
    Jonas Grossman
     

    Title:
    Chief Executive Officer
     

 

 

2

 



 






